Why the study?
What is the role of ivabradine and trimetazidine in the management of heart failure according to the 2016 ESC guidelines?
What is the role of ivabradine and trimetazidine in the management of heart failure according to the 2016 ESC guidelines?
This review highlights the 2016 ESC guideline recommendations for using ivabradine and trimetazidine as therapeutic options in specific heart failure populations.
Answers are grounded in this paper and cite their sources.
Supports 2016 ESC-directed ivabradine and trimetazidine use in select HF; leaves open integration with post-2016 therapies.
The prevalence of heart failure (HF) is increasing, representing a major cause of death and disability, and a growing financial burden on healthcare systems. Despite the use of effective treatments with both drugs and devices, mortality remains high. There is therefore a need for new and effective therapeutic agents. Ivabradine is a specific sinus node inhibiting agent that was approved in 2005 by the European Medicines Agency, alone or in combination with a beta-blocker. Trimetazidine is a cytoprotective, anti-ischaemic agent established in the treatment of angina pectoris. In the 2012 European Society of Cardiology (ESC) guidelines for diagnosis and treatment of HF, ivabradine was recommended in symptomatic HF patients who are in sinus rhythm with left ventricular ejection fraction ≤35 % and heart rate higher than 70 beats per minute, despite optimal medical therapy, including maximally tolerated dose of beta-blocker. The role of trimetazidine in this setting was not mentioned. In the 2016 ESC guidelines, recommendations for ivabradine are unchanged but trimetazidine is included for the treatment of angina pectoris with HF. This article discusses the need for new therapeutic options in HF and reviews clinical evidence in support of these two therapeutic options.
No takes yet. Share an insight, caveat, or question.
Milinković et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: